Cited by 112RNA Interference and Gene DeliveryImmunotherapy and Immune ResponsesImmune Response and Inflammation

The DOI matches its Crossref record; 149 of the 150 references it cites were found in a registry or an index.

Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger.

Open access

Devoldere, Joke, Dewitte, Heleen, De Smedt, Stefaan C., Remaut, Katrien·2016·Drug Discovery Today

DOI 10.1016/j.drudis.2015.07.009

Open this paper in CoChat — free account Open PDF

Abstract

In the field of nonviral gene therapy, in vitro transcribed (IVT) mRNA has emerged as a promising tool for the delivery of genetic information. Over the past few years it has become widely known that the introduction of IVT mRNA into mammalian cells elicits an innate immune response that has favored mRNA use toward immunotherapeutic vaccination strategies. However, for non-immunotherapy-related applications this intrinsic immune-stimulatory activity directly interferes with the aimed therapeutic outcome, because it can seriously compromise the expression of the desired protein. This review presents an overview of the immune-related obstacles that limit mRNA advance for non-immunotherapy-related applications.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2015.07.009

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,486
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,976
Toll-like receptor signalling
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Toll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., & Fujita, T. (2004) · Nature Immunology · doi:10.1038/ni1087 · Cited by 4,022
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508

Show all 150 references

Sorted by citations

Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584
Nanomaterial Delivery Systems for mRNA Vaccines
Buschmann, M. D., Carrasco, M. J., Alishetty, S., Paige, M., Alameh, M. G., & Weissman, D. (2021) · Vaccines · doi:10.3390/vaccines9010065 · Cited by 582
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560
The landscape of mRNA nanomedicine
Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., & Tao, W. (2022) · Nature Medicine · doi:10.1038/s41591-022-02061-1 · Cited by 511
Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376
Impact of mRNA chemistry and manufacturing process on innate immune activation
Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6893 · Cited by 354
COVID-19 mRNA vaccines: Platforms and current developments
Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308
Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9
Zhang, H., Zhang, Y., & Yin, H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.014 · Cited by 256
Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination
Persano, S., Guevara, M. L., Li, Z., Mai, J., Ferrari, M., Pompa, P. P., & Shen, H. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.019 · Cited by 187
Nanoscale platforms for messenger RNA delivery
Li, B., Zhang, X., & Dong, Y. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1530 · Cited by 170
Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across
Minnaert, A.-K., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S. C., Raemdonck, K., Sanders, N. N., & Remaut, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113900 · Cited by 157
Self-citation
Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics—An innate immune system standpoint
Granot-Matok, Y., & Peer, D. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.015 · Cited by 160
Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP
Lin, Y., Wagner, E., & Lächelt, U. (2022) · Biomaterials Science · doi:10.1039/d1bm01658j · Cited by 148
Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA
Verbeke, R., Lentacker, I., Wayteck, L., Breckpot, K., Van Bockstal, M., Descamps, B., Vanhove, C., De Smedt, S. C., & Dewitte, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.041 · Cited by 132
Self-citation
Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon
Broos, K., Van der Jeught, K., Puttemans, J., Goyvaerts, C., Heirman, C., Dewitte, H., Verbeke, R., Lentacker, I., Thielemans, K., & Breckpot, K. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.38 · Cited by 121
Self-citation
mRNA therapeutics deliver a hopeful message
Zhong, Z., Cafferty, S. M., Combes, F., Huysmans, H., Temmerman, J. D., Gitsels, A., Vanrompay, D. C. G., Catani, J. P., & Sanders, N. N. (2018) · Nano Today · doi:10.1016/j.nantod.2018.10.005 · Cited by 124
Non-immunotherapy application of LNP-mRNA: Maximizing efficacy and safety
Vlatkovic, I. (2021) · Biomedicines · doi:10.3390/biomedicines9050530 · Cited by 112
Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2
Granados-Riveron, J. T., & Aquino‐Jarquín, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111953 · Cited by 115
Exosomes for mRNA delivery: a novel biotherapeutic strategy with hurdles and hope
Aslan, C., Kiaie, S. H., Zolbanin, N. M., Lotfinejad, P., Ramezani, R., Kashanchi, F., & Jafari, R. (2021) · BMC Biotechnology · doi:10.1186/s12896-021-00683-w · Cited by 113
Neo-Antigen mRNA Vaccines
Esprit, A., de Mey, W., Shahi, R. B., Thielemans, K., Franceschini, L., & Breckpot, K. (2020) · Vaccines · doi:10.3390/vaccines8040776 · Cited by 112
The advent of clinical self-amplifying RNA vaccines
Casmil, I. C., Jin, J., Won, E.-J., Huang, C., Liao, S., Cha‐Molstad, H., & Blakney, A. K. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.060 · Cited by 111
Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells
Verbeke, R., Lentacker, I., Breckpot, K., Janssens, J., Calenbergh, S. V., Smedt, S. C. D., & Dewitte, H. (2019) · ACS Nano · doi:10.1021/acsnano.8b07660 · Cited by 85
Self-citation
Eliciting antitumor immunity via therapeutic cancer vaccines
Peng, K., Zhao, X., Fu, Y., & Liang, Y. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01316-4 · Cited by 104
mRNA in cancer immunotherapy: beyond a source of antigen
Hoecke, L. V., Verbeke, R., Dewitte, H., Lentacker, I., Vermaelen, K. Y., Breckpot, K., & Lint, S. V. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01329-3 · Cited by 85
Self-citation
Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages
Moradian, H., Roch, T., Anthofer, L., Lendlein, A., & Gossen, M. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.004 · Cited by 77
Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges
Steinle, H., Behring, A., Schlensak, C., Wendel, H. P., & Avci‐Adali, M. (2016) · Stem Cells · doi:10.1002/stem.2402 · Cited by 78
Intracellular Delivery of mRNA in Adherent and Suspension Cells by Vapor Nanobubble Photoporation
Raes, L., Stremersch, S., Fraire, J. C., Brans, T., Goetgeluk, G., Munter, S. D., Hoecke, L. V., Verbeke, R., Hoeck, J. V., Xiong, R., et al. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00523-0 · Cited by 76
Non-viral delivery of chemically modified mRNA to the retina: Subretinal versus intravitreal administration
Devoldere, J., Peynshaert, K., Dewitte, H., Vanhove, C., Groef, L. D., Moons, L., Özcan, S. Y., Dalkara, D., Smedt, S. C. D., & Remaut, K. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.042 · Cited by 70
Self-citation
Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies
Hameed, S. A., Paul, S., Dellosa, G. K. Y., Jaraquemada, D., & Bello, M. B. (2022) · npj Vaccines · doi:10.1038/s41541-022-00485-x · Cited by 65
Delivery of mRNA for regulating functions of immune cells
Shi, J. Y., Huang, M., Lu, Z.-D., Du, X., Shen, S., Xu, C., & Wang, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.033 · Cited by 62
Therapeutic mRNA delivery to leukocytes
Granot-Matok, Y., Kon, E., Dammes, N., Mechtinger, G., & Peer, D. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.032 · Cited by 64
Understanding the impact of in vitro transcription byproducts and contaminants
Lenk, R., Kleindienst, W., Szabó, G. T., Baiersdörfer, M., Boros, G., Keller, J. M., Mahiny, A. J., & Vlatkovic, I. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1426129 · Cited by 63
Subretinal therapy: technological solutions to surgical and immunological challenges
Ladha, R., Caspers, L. E., Willermain, F., & de Smet, M. D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.846782 · Cited by 54
Biologics and their delivery systems: Trends in myocardial infarction
Borrelli, M. A., Turnquist, H. R., & Little, S. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.014 · Cited by 56
Analyzing immune responses to varied mRNA and protein vaccine sequences
Park, H.-J., Bang, Y., Kwon, S. P., Kwak, W., Park, S., Roh, G., Bae, S., Kim, J., Kwak, H. W., Kim, Y., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00684-0 · Cited by 53
Emerging Concepts of Nanobiotechnology in mRNA Delivery
Wang, Y., & Yu, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202003545 · Cited by 54
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
de Vyver, T. V., Smedt, S. C. D., & Raemdonck, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114041 · Cited by 51
The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy
Campillo-Davó, D., Laere, M. D., Roex, G., Versteven, M., Flumens, D., Berneman, Z. N., Tendeloo, V. F. V., Anguille, S., & Lion, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030396 · Cited by 50
Corticosteroids and cellulose purification improve, respectively, the in vivo translation and vaccination efficacy of sa-mRNAs
Zhong, Z., McCafferty, S., Opsomer, L., Wang, H., Huysmans, H., De Temmerman, J., Lienenklaus, S., Portela Catani, J. P., Combes, F., & Sanders, N. N. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.023 · Cited by 48
The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics
Muslimov, A. R., Tereshchenko, V., Shevyrev, D., Rogova, A. S., Lepik, K. V., Reshetnikov, V. V., & Ivanov, R. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914820 · Cited by 51
Fluorescence Correlation Spectroscopy to find the critical balance between extracellular association and intracellular dissociation of mRNA complexes
Zhang, H., Smedt, S. C. D., & Remaut, K. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.05.016 · Cited by 46
Self-citation
RNA Therapeutics: How Far Have We Gone?
Coutinho, M. F., Matos, L., Santos, J. I., & Alves, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-19966-1_7 · Cited by 45
Delivery vehicle and route of administration influences self-amplifying RNA biodistribution, expression kinetics, and reactogenicity
Bathula, N. V., Friesen, J. J., Casmil, I. C., Wayne, C. J., Liao, S., Soriano, S. K. V., Ho, C.-H., Strumpel, A., & Blakney, A. K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.078 · Cited by 44
Together is Better: mRNA Co‐Encapsulation in Lipoplexes is Required to Obtain Ratiometric Co‐Delivery and Protein Expression on the Single Cell Level
Zhang, H., Bussmann, J., Huhnke, F. H., Devoldere, J., Minnaert, A., Jiskoot, W., Serwane, F., Spatz, J. P., Röding, M., Smedt, S. C. D., et al. (2021) · Advanced Science · doi:10.1002/advs.202102072 · Cited by 37
Self-citation
Sustained release of PKR inhibitor C16 from mesoporous silica nanoparticles significantly enhances mRNA translation and anti-tumor vaccination
Zhang, W., Liu, Y., Chin, J. M., & Phua, K. K. L. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.011 · Cited by 33
Pre-clinical non-viral vectors exploited for in vivo CRISPR/Cas9 gene editing: an overview
Rouatbi, N., McGlynn, T., & Al‐Jamal, K. T. (2022) · Biomaterials Science · doi:10.1039/d1bm01452h · Cited by 33
In Vitro Transcribed mRNA Vaccines with Programmable Stimulation of Innate Immunity
Loomis, K. H., Lindsay, K. E., Zurla, C., Bhosle, S. M., Vanover, D. A., Blanchard, E. L., Kirschman, J. L., Bellamkonda, R. V., & Santangelo, P. J. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00443 · Cited by 32
mRNA-Based Vaccines and Mode of Action
Gergen, J., & Petsch, B. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_230 · Cited by 36
The obstacle course to the inner retina: Hyaluronic acid-coated lipoplexes cross the vitreous but fail to overcome the inner limiting membrane
Devoldere, J., Wels, M., Peynshaert, K., Dewitte, H., Smedt, S. C. D., & Remaut, K. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.05.023 · Cited by 30
Self-citation
An old problem with new solutions: Strategies to improve vaccine efficacy in the elderly
Bell, M. R., & Kutzler, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114175 · Cited by 29
Inhibition of the Inflammatory Pathway Enhances Both the in Vitro and in Vivo Transfection Activity of Exogenous in Vitro-Transcribed mRNAs Delivered by Lipid Nanoparticles
Ohto, T., Konishi, M., Tanaka, H., Onomoto, K., Yoneyama, M., Nakai, Y., Tange, K., Yoshioka, H., & Akita, H. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00783 · Cited by 29
Clinical potential of oligonucleotide-based therapeutics in the respiratory system
Moschos, S. A., Usher, L., & Lindsay, M. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.009 · Cited by 26
Mannich reaction-based combinatorial libraries identify antioxidant ionizable lipids for mRNA delivery with reduced immunogenicity
Gong, N., Kim, D., Alameh, M., El-Mayta, R. D., Han, E. L., Dwivedi, G., Palanki, R., Shi, Q., Han, X., Xue, L., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01422-8 · Cited by 34
Tackling pharmacological response heterogeneity by PBPK modeling to advance precision medicine productivity of nanotechnology and genomics therapeutics
Vizirianakis, I. S., Miliotou, Α. N., Mystridis, G. A., Andriotis, E. G., Andreadis, I. I., Papadopoulou, L. C., & Fatouros, D. G. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1605828 · Cited by 25
Aerosolized Non-viral Nucleic Acid Delivery in the Vaginal Tract of Pigs
Remaut, K., Clercq, E. D., Andries, O., Rombouts, K., Gils, M. V., Cicchelero, L., Vandenbussche, I., Praet, S. V., Benito, J. M., Fernández, J. M. G., et al. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1796-x · Cited by 25
Self-citation
Strategies for modulating innate immune activation and protein production of in vitro transcribed mRNAs
Loomis, K. H., Kirschman, J. L., Bhosle, S. M., Bellamkonda, R. V., & Santangelo, P. J. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb01753j · Cited by 24
Co-Delivery of mRNA and pDNA Using Thermally Stabilized Coacervate-Based Core-Shell Nanosystems
Nasr, S. S., Lee, S., Thiyagarajan, D., Boese, A. S., Loretz, B., & Lehr, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111924 · Cited by 22
Messenger RNA translation enhancement by immune evasion proteins: a comparative study between EKB (vaccinia virus) and NS1 (influenza A virus)
Liu, Y., Chin, J. M., Choo, E. L., & Phua, K. K. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-48559-6 · Cited by 22
mRNA Therapies: New Hope in the Fight against Melanoma
van Dülmen, M., & Rentmeister, A. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00181 · Cited by 22
Kinetic analysis of IFIT1 and IFIT5 interactions with different native and engineered RNAs and its consequences for designing mRNA-based therapeutics
Miedziak, B., Dobieżyńska, A., Darżynkiewicz, Z. M., Bartkowska, J., Miszkiewicz, J., Kowalska, J., Warmiński, M., Tyras, M., Trylska, J., Jemielity, J., et al. (2019) · RNA · doi:10.1261/rna.073304.119 · Cited by 21
Protein Expression Correlates Linearly with mRNA Dose over Up to Five Orders of Magnitude In Vitro and In Vivo
van Asbeck, A. H., Dieker, J. W. C., Egberink, R. O., van den Berg, L., van der Vlag, J., & Brock, R. E. (2021) · Biomedicines · doi:10.3390/biomedicines9050511 · Cited by 21
Efficient reduction of synthetic mRNA induced immune activation by simultaneous delivery of B18R encoding mRNA
Michel, T., Golombek, S., Steinle, H., Hann, L., Velić, A., Maček, B., Krajewski, S., Schlensak, C., Wendel, H. P., & Avci‐Adali, M. (2019) · Journal of Biological Engineering · doi:10.1186/s13036-019-0172-5 · Cited by 21
Less is more: Self-amplifying mRNA becomes self-killing upon dose escalation in immune-competent retinal cells
Vanluchene, H., Gillon, O., Peynshaert, K., Smedt, S. C. D., Sanders, N. N., Raemdonck, K., & Remaut, K. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114204 · Cited by 19
Self-citation
Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV
D’haese, S., Lacroix, C., García, F., Plana, M., Ruță, S. M., Vanham, G. L., Verrier, B., & Aerts, J. L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.009 · Cited by 18
Low Resource Integrated Platform for Production and Analysis of Capped mRNA
Nwokeoji, A. O., Chou, T.-C., & Nwokeoji, E. A. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00609 · Cited by 18
Analysis of critical protein–protein interactions of SARS-CoV-2 capping and proofreading molecular machineries towards designing dual target inhibitory peptides
Arabi-Jeshvaghani, F., Javadi‐Zarnaghi, F., & Ganjalikhany, M. R. (2023) · Scientific Reports · doi:10.1038/s41598-022-26778-8 · Cited by 17
Co-delivery of NS1 and BMP2 mRNAs to murine pluripotent stem cells leads to enhanced BMP-2 expression and osteogenic differentiation
Wang, P., Logeart‐Avramoglou, D., Petite, H., Gonçalves, C., Midoux, P., Perche, F., & Pichon, C. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.03.045 · Cited by 17
Small molecules convey big messages: Boosting non-viral nucleic acid delivery with low molecular weight drugs
Joris, F., Smedt, S. C. D., & Raemdonck, K. (2017) · Nano Today · doi:10.1016/j.nantod.2017.06.012 · Cited by 17
Keratinocyte Growth Factor Modified Messenger RNA Accelerating Cell Proliferation and Migration of Keratinocytes
Denzinger, M., Link, A., Kurz, J., Krauß, S., Thoma, R., Schlensak, C., Wendel, H. P., & Krajewski, S. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0737 · Cited by 17
Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer
Breusa, S., Zilio, S., Catania, G., Bakrin, N., Kryza, D., & Lollo, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1125868 · Cited by 17
Emerging Therapeutic RNAs for the Targeting of Cancer Associated Fibroblasts
Santana-Viera, L., Ibba, M. L., Rotoli, D., Catuogno, S., & Esposito, C. L. (2020) · Cancers · doi:10.3390/cancers12061365 · Cited by 15
Application of Peptides in Construction of Nonviral Vectors for Gene Delivery
Yang, Y., Liu, Z., Ma, H., & Cao, M. (2022) · Nanomaterials · doi:10.3390/nano12224076 · Cited by 14
MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease
Brault, J., Meis, R. J., Li, L., Bello, E. A., Liu, T., Sweeney, C. L., Koontz, S. M., Dowdell, K., Theobald, N., Lee, J. S., et al. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.08.013 · Cited by 14
The Interplay Between Therapeutic Self-Amplifying RNA and the Innate Immune System: Balancing Efficiency and Reactogenicity
Kunyk, D., Plotnikova, M. A., Bespalov, M., Shevyrev, D., Klotchenko, S. A., Ivanov, R. A., & Reshetnikov, V. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188986 · Cited by 17
Exploring the Potential and Advancements of Circular RNA Therapeutics
Wang, L., Wang, L., Dong, C., Liu, J., Cui, G., Gao, S., & Liu, Z. (2025) · Exploration · doi:10.1002/exp.20240044 · Cited by 15
Suppression of mRNA Nanoparticle Transfection in Human Fibroblasts by Selected Interferon Inhibiting Small Molecule Compounds
Liu, Y., Krishnan, M. N., & Phua, K. K. L. (2017) · Biomolecules · doi:10.3390/biom7030056 · Cited by 10
Engineering of regulatory T cells by means of mRNA electroporation in a GMP-compliant manner
Janssens, I., Campillo-Davó, D., den Bos, J. V., Reu, H. D., Berneman, Z. N., Wens, I., & Cools, N. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.01.001 · Cited by 10
mRNA Vaccines: Design Principles, Mechanisms, and Manufacturing—Insights From COVID‐19 as a Model for Combating Infectious Diseases
Sokhangouy, S. K., Behzadi, M., Rezaei, S., Farjami, M., Haghshenas, M., Sefidbakht, Y., & Mozaffari‐Jovin, S. (2025) · Biotechnology Journal · doi:10.1002/biot.202400596 · Cited by 9
Charge-Complementary Polymersomes for Enhanced mRNA Delivery
Kim, H., Ahn, Y., Kim, M., Choi, J., Shin, S., & Kim, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122781 · Cited by 8
Strategic deactivation of mRNA COVID‐19 vaccines: New applications for siRNA therapy and RIBOTACs
Hulscher, N., McCullough, P. A., & Marotta, D. E. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.3733 · Cited by 9
Influence of pathogenic stimuli on Müller cell transfection by lipoplexes
Peynshaert, K., Devoldere, J., Philips, F., Vergauwe, F., Smedt, S. C. D., & Remaut, K. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.03.009 · Cited by 8
Self-citation
Protein Transduction Domain-Mediated Delivery of Recombinant Proteins and In Vitro Transcribed mRNAs for Protein Replacement Therapy of Human Severe Genetic Mitochondrial Disorders: The Case of Sco2 Deficiency
Miliotou, Α. N., Foltopoulou, P. F., Ingendoh‐Tsakmakidis, A., Tsiftsoglou, A. S., Vizirianakis, I. S., Pappas, I. S., & Papadopoulou, L. C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010286 · Cited by 7
Supramolecular Gene Transfection Agents
Pitard, B., & Habrant, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12563-6 · Cited by 8
Payload‐Driven Design of Polymeric Carriers for Nucleic Acid Delivery: Insights from Structure–Function Relationships
Moradian, H., Dunne, C. M., Gossen, M., & Hartlieb, M. (2025) · Advanced Science · doi:10.1002/advs.202512653 · Cited by 6
Vaccinia Virus Protein B18R: Influence on mRNA Immunogenicity and Translation upon Non-Viral Delivery in Different Ocular Cell Types
Minnaert, A., Devoldere, J., Peynshaert, K., Vercruysse, L., Smedt, S. C. D., & Remaut, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010074 · Cited by 6
Self-citation
Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
Michel, T., Link, A., Abraham, M.-K., Schlensak, C., Peter, K., Wendel, H.-P., Wang, X., & Krajewski, S. (2019) · Journal of Visualized Experiments · doi:10.3791/58444 · Cited by 7
Controlling Protein Expression by Delivery of RNA Therapeutics Using Lipid Nanoparticles
Lin, P. J. C., & Tam, Y. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814470-1.00009-5 · Cited by 6
Electroporation of mRNA as a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins
Sauerer, T., Albrecht, L., Sievers, N. M., Gerer, K. F., Hoyer, S., Dörrie, J., & Schaft, N. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3770-8_10 · Cited by 5
Intracellular RNase activity dampens zinc finger nuclease-mediated gene editing in hematopoietic stem and progenitor cells
Peterson, C. W., Venkataraman, R., Reddy, S. S., Pande, D., Enstrom, M., Radtke, S., Humbert, O., & Kiem, H. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.11.010 · Cited by 7
RNA technology and nanocarriers empowering in vivo chimeric antigen receptor therapy
Cai, J., Chen, S., Liu, Z., Li, H., Wang, P., Yang, F., Li, Y., Chen, K., Sun, M., & Qiu, M. (2024) · Immunology · doi:10.1111/imm.13861 · Cited by 5
General method for the production of hydrogel droplets from uniformly sized smart shell membranes
Gwon, S.-J., & Park, S. (2020) · Polymer Chemistry · doi:10.1039/d0py00679c · Cited by 5
Moderne Konzepte der Nanobiotechnologie für mRNA‐Abgabesysteme
Wang, Y., & Yu, C. (2020) · Angewandte Chemie · doi:10.1002/ange.202003545 · Cited by 4
NADPH oxidase correction by mRNA transfection of apheresis granulocytes in chronic granulomatous disease
Ravin, S. S. D., Brault, J., Meis, R. J., Li, L., Theobald, N., Bonifacino, A. C., Lei, H., Liu, T., Koontz, S. M., Corsino, C. I., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003224 · Cited by 4
The Efficiency of Brain‐Derived Neurotrophic Factor Secretion by mRNA‐Electroporated Regulatory T Cells Is Highly Impacted by Their Activation Status
den Bos, J. V., Janssens, I., Vermeulen, M., Dams, A., Reu, H. D., Peeters, S., Faghel, C., Ouaamari, Y. E., Wens, I., & Cools, N. (2024) · European Journal of Immunology · doi:10.1002/eji.202451005 · Cited by 3
Harnessing dendritic cells as immunological bridges to potentiate mRNA cancer vaccines
Wu, R., Li, H., Li, Z., Hao, K., & Tian, H. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00995b · Cited by 3
Deconvolution of synthetic mRNA expression: Nucleoside chemistry alters translatability
Moradian, H., Schwestka, M., Roch, T., & Gossen, M. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10622 · Cited by 3
Iterative Upgrading of mRNA Therapeutics by Modulating the Microenvironment for Translation
Shi, Y., Lou, Z., Wang, Y., Li, M., Wang, Y., & You, J. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202414722 · Cited by 1
Influenza A virus derived NS1 enhances translation of HPLC purified mRNA and interferon adjuvanted mRNA vaccination
Phua, K. K. L., Liu, Y., Zhang, W., Chin, J. M., Tang, H.-W., Pardi, N., & Nair, S. K. (2026) · Scientific Reports · doi:10.1038/s41598-026-35611-5 · Cited by 1
Elastin production by mRNA technology for rejuvenation of aged skin
Shi, Y., Lou, Z., Chen, Y., Xu, J., Zhang, Z., Zhang, Z., Gao, Y., Wang, Y., & You, J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115033 · Cited by 1

Authors: Devoldere, J., Dewitte, H., De Smedt, S. C., & Remaut, K.
Affiliations: Ghent University (BE)
Corresponding author: Remaut, Katrien
ORCID: Dewitte, Heleen
Remaut, Katrien
Venue: Drug Discovery Today
Publisher: Elsevier BV
Published: 2016-01
Volume: 21
Issue: 1
Pages: 11-25
ISSN: 1359-6446 (ISSN-L)
DOI: 10.1016/j.drudis.2015.07.009
OpenAlex: W1529085705
Cited by: 112
References: 150
Citations by year: 2026: 4 · 2025: 9 · 2024: 10 · 2023: 9 · 2022: 16 · 2021: 18 · 2020: 16 · 2019: 14 · 2018: 5 · 2017: 5 · 2016: 4
FWCI: 0.52
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Drug Discovery Today (publishedVersion)
PubMed (publishedVersion)
Ghent University Academic Bibliography (Ghent University) (publishedVersion)
Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
Funders: European Molecular Biology Laboratory
Fonds Wetenschappelijk Onderzoek
Universiteit Gent
Vlaamse regering
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Keywords: in vitro transcribed mRNA, innate immunity, immune evasion, non-viral gene therapy, mRNA expression
MeSH terms: Animals, Humans, Immunity, Innate, Immunotherapy, RNA, Messenger, Genetic Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks